For his work in the development of ALZ-801, a small molecule inhibitor of beta-amyloid oligomer formation and neurotoxicity, showing promise in slowing or reversing cognitive impairment caused by Alzheimer’s.
Prior to founding Alzheon, Dr. Tolar held executive positions in life sciences companies, where he established and grew new companies, business areas, and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., President & CEO at NormOxys, Inc., and as Chief Scientific Officer and Chief Business Officer at CoMentis, Inc., where he built the first clinical beta secretase inhibitor platform and negotiated a deal for the program for $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, where he was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approval including NDA filings. During his academic career, Dr. Tolar served as an Assistant Professor in the Department of Neurology at Yale University School of Medicine. Dr. Tolar was recognized as one of the Top 100 Most Influential People in the world of drug development and manufacture by The Medicine Maker Magazine’s Power Lists for 2016, 2017, and 2018.
Photos from the 2019 Cure Coin Award Ceremony - July 2019 - The Association, LA